A comprehensive review of caffeine population pharmacokinetics in preterm infants: Factors affecting clearance

被引：0
作者：
He, Yaodong [1 ,2 ]
Shen, Xianhuan [1 ]
Zhu, Jiahao [1 ]
Zhang, Lian [1 ]
Wang, Xixuan [1 ,2 ]
Zhou, Tao [1 ]
Zhang, Jianping [2 ]
Li, Wenzhou [1 ]
Fan, Xiaomei [1 ]
机构：
[1] Shenzhen Baoan Womens & Childrens Hosp, Dept Pharm, Shenzhen 518102, Guangdong, Peoples R China
[2] Jinan Univ, Coll Pharm, Dept Clin Pharmacol, Guangzhou 510632, Guangdong, Peoples R China
来源：
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS | 2025年 / 208卷
关键词：
Population pharmacokinetics; Caffeine; Preterm infant; Clearance; Individualized dosing regimen; DRIED BLOOD SPOTS; PLASMA; APNEA; ERYTHROPOIETIN; INTOLERANCE;
D O I：
10.1016/j.ejpb.2025.114659
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Caffeine is an FDA-approved drug for preventing and treating apnea in preterm infants. However, the pharmacokinetic (PK) characteristics of caffeine in preterm infants differ significantly from those in adults. Several population pharmacokinetic (PopPK) models have been developed to investigate potential covariates influencing PK parameters. This review aimed to summarize PopPK studies of caffeine in preterm infants and explore the identified influencing covariates. It has been observed that most caffeine pharmacokinetics followed a onecompartment model (1-CMT), although one study utilized a three-compartment model (3-CMT). Various covariates including birth weight, current weight, genetic polymorphism, combination medications, feeding patterns, and pathological conditions have been identified to affect caffeine PK parameters in preterm infants. Developing an individualized dosing regimen for preterm infants is essential for safe and effective treatment. Future PopPK studies of caffeine in preterm infants should focus on sampling and feeding patterns and further explore the effects of other covariates like gestational and postnatal age on caffeine PK parameters, which should be taken into account in the individualized dosing regimen of caffeine.
引用
收藏
页数：9
相关论文
共 51 条
  • [1] Chavez L., Bancalari E., Caffeine: some of the evidence behind its use and abuse in the preterm infant, Neonatology, 119, 4, pp. 428-432, (2022)
  • [2] Sakaria R.P., Dhanireddy R., Pharmacotherapy in bronchopulmonary dysplasia: what is the evidence?, Front Pediatr., 10, (2022)
  • [3] Conlon S., Di Fiore J.M., Martin R.J., Are we over-treating hypoxic spells in preterm infants?, Semin Fetal Neonatal Med., 26, 3, (2021)
  • [4] Hwang J., Kim Y.S., Shin J.H., Et al., Hemodynamic effects on systemic blood flow and ductal shunting flow after loading dose of intravenous caffeine in preterm infants according to the patency of ductus arteriosus, J Korean Med Sci., 33, 4, (2018)
  • [5] Yang L., Yu X., Zhang Y., Et al., Encephalopathy in preterm infants: advances in neuroprotection with caffeine, Front Pediatr., 9, (2021)
  • [6] Carroll L., Owen L.A., Current evidence and outcomes for retinopathy of prematurity prevention: insight into novel maternal and placental contributions, Explor Med., 1, pp. 4-26, (2020)
  • [7] Prasad M., Ingolfsland E.C., Christiansen S.P., Modifiable risk factors and preventative strategies for severe retinopathy of prematurity, Life (basel), 13, 5, (2023)
  • [8] Yang K., Liu J., He T., Et al., Caffeine and neonatal acute kidney injury, Pediatr Nephrol, 39, 5, pp. 1355-1367, (2024)
  • [9] Giacoia G.P., Jungbluth G.L., Jusko W.J., Effect of formula feeding on oral absorption of caffeine in premature infants, Dev Pharmacol Ther., 12, 4, pp. 205-210, (1989)
  • [10] Aranda J.V., Beharry K.D., Pharmacokinetics, pharmacodynamics and metabolism of caffeine in newborns, Semin Fetal Neonatal Med., 25, 6, (2020)
123456